Evercore ISI raised the firm’s price target on Baxter to $58 from $55 and keeps an Outperform rating on the shares, which the analyst is also adding to the firm’s “Tactical Outperform” list ahead of earnings from the MedTech, Life Science Tools and Diagnostics group. Evercore has “a distinct bias towards mega caps and value/GARP as we head into” Q2, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAX: